
Home » Bayer’s Radium-223 granted Fast Track Designation
Bayer’s Radium-223 granted Fast Track Designation
August 23, 2011
Bayer HealthCare Pharmaceuticals’ investigational compound radium-223 chloride, which is exclusively licensed from Algeta ASA, has been granted Fast Track designation by the FDA for the treatment of castration-resistant (hormone-refractory) prostate cancer in patients with bone metastases.
Radium-223 chloride is an investigational agent and is not approved by the FDA, the European Medicines Agency (EMA) or other Health Authorities.
"We are pleased that the FDA has granted Fast Track designation to radium-223 chloride," said Kemal Malik, MD, head of global development and member of the Bayer HealthCare executive committee.
Upcoming Events
-
14Apr